Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dky539
Abstract: BACKGROUND Posaconazole delayed-release tablets offer better bioavailability than the liquid suspension, but no post-marketing data are available in immunocompetent hosts such as those with chronic pulmonary aspergillosis (CPA). OBJECTIVES To explore the pharmacokinetics and adverse… read more here.
Keywords: posaconazole tablets; chronic pulmonary; aspergillosis; pulmonary aspergillosis ... See more keywords